Sara Fuchs Professor Sara Fuchs
The Sir Ernst B. Chain Professor of Neuroimmunology

 List of Publications (last 3 years):

  1. H. Steiner, S. Fuchs and D. Accili. D3 dopamine receptor-deficient mouse: Evidence for reduced anxiety. Physiology and Behavior, 63, 137-141 (1998).
  2. D. Barchan, O. Asher, S.J. Tzartos, S. Fuchs and M.C. Souroujon. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur. J. Immunol., 28, 616-624 (1998).
  3. O. Asher, B.S. Jensen, M. Lupu-Meiri, Y. Oron and S. Fuchs. The mongoose acetylcholine receptor a-subunit: analysis of glycosylation and -bungarotoxin binding. FEBS Lett., 426, 212-216 (1998).
  4. S. Ariel, O. Asher, D. Barchan, M. Ovadia and S. Fuchs. The mongoose neuronal acetylcholine receptor (7) binds -bungarotoxin. Ann. N.Y. Acad. Sci., 841. 93-96 (1998).
  5. O. Asher, M. Lupu-Meiri, B.S. Jensen, T. Paperna, Y. Oron and S. Fuchs. How does the mongoose cope with -bungarotoxin? Analysis of the mongoose muscle AChR -subunit. Ann. N.Y. Acad. Sci., 841, 97-100 (1998).
  6. M.C. Souroujon, D. Barchan and S. Fuchs. Modulation of experimental autoimmune myasthenia gravis by recombinant fragments of the human acetylcholine receptor. Ann. N.Y. Acad. Sci., 841, 572-575 (1998).
  7. C. Mauger, B. Sivan, M. Bockhaus, S. Fuchs, O. Civelli and F. Monsma. Development and characterization of anti-peptide antibodies against the mouse D4 dopamine receptor. Eur. J. Neurosci., 10, 529-537 (1998).
  8. J. Drago, P. Padungchaichot, D. Accili and S. Fuchs. Dopamine receptors and dopamine transporter in brain function and addictive behaviors: Insights from targeted mouse mutants. Developmental Neuroscience, 20, 188-203 (1998).
  9. O. Asher, M. Lupu-Meiri, B.S. Jensen, T. Paperna, S. Fuchs and Y. Oron. Functional characterization of mongoose nicotinic acetylcholine receptor -subunit resistance to -bungarotoxin and high sensitivity to acetylcholine. FEBS Lett., 431, 411-414 (1998).
  10. L.D. Asico, C. Ladines, S. Fuchs, D. Accili, R.M. Carey, C. Semeraro, F. Pocchiari, R. Felder, G.M. Eisner and P.A. Jose. Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J. Clin. Invest.,102, 493-498 (1998).
  11. B. Levavi-Sivan, B.-H. Park, S. Fuchs and C.S. Fishburn. Human D3 dopamine receptor in the meduloblastoma TE671 cell line: Cross talk between D1 and D3 receptors. FEBS Lett., 439, 138-142 (1998).
  12. S. Fuchs. Antigen-specific immunomodulation of experimental auto-immune myasthenia gravis. In "The Decade of Autoimmunity". Y. Shoenfeld, ed., Elsevier Sci. Publishers, Amsterdam, pp. 255-260 (1999).
  13. J. Obadiah, T. Avidor-Reiss, C.S. Fishburn, S. Carmon, M. Bayewitch, Z. Vogel, S. Fuchs and B. Levavi-Sivan. Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz and Gs. Cell. Mol. Neurobiol., 19, 653-664 (1999).
  14. S. Fuchs, S.-H. Im,, D. Barchan and M.C. Souroujon. Antigen-specific therapy of experimental autoimmune myasthenia gravis: Mucosal tolerance with recombinant fragments of the human acetylcholine receptor. In: "Myasthenia Gravis". P. Christadoss, ed., Narosa Publishing House, pp. 172-180 (1999).
  15. D. Barchan, M.C. Souroujon, S.-H. Im, C. Antozzi and S. Fuchs. Antigen-specific immunotherapy of experimental myasthenia: nasal tolerization with recombinant fragments of the human acetylcholine receptor -subunit. Proc. Natl. Acad. Sci. USA, 96, 8086-8091 (1999).
  16. S.-H. Im, D. Barchan, S. Fuchs and M. C. Souroujon. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest., 104, 1723-1730 (1999).
  17. N. Venkatesh, S.-H. Im, M. Balass, S. Fuchs and E. Katchalski-Katzir. Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide. Proc. Natl. Acad. Sci. USA, 97, 761-766 (2000).
  18. S.-H. Im, D. Barchan, M. C. Souroujon and S. Fuchs. Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis. J. Immunol., 165, 3599-3605 (2000).
  19. S.-H. Im, D. Barchan, S. Fuchs and M. C. Souroujon. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for trearment of experimental myasthenia gravis. J. Neuroimmunol. 111, 161-168 (2000).
  20. R. Kasher, M. Balass, T. Scherf, M. Fridkin, S. Fuchs and E. Katchalski-Katzir. Design and synthesis of peptides that bind -bungarotoxin with high affinity. Chemistry and Biology, 8, 147-155 (2001).
  21. C. Betancur, I. Lepee-Lorgeoux, M. Cazillis, D. Accili, S. Fuchs and W. Rostene. Neurotensin gene expression and behavioral responses following administration of psychostimulants and antipsychotic drugs in dopamine D3 receptor deficient mice. Neuropsychopharmacology 24, 170-182 (2001).
  22. A.S. Gordon, L. Yao, Z. Jiang, C. S. Fishburn, S. Fuchs, and I. Diamond. Ethanol acts synergistically with a dopamine agonist to cause translocation of PKC. Mol. Pharmacol. 59, 153-160 (2001).
  23. T. Ilani, D. Ben-Shachar, R. D. Strous, M. Mazor, A. Sheinkman, M. Kotler and S. Fuchs. A novel peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad. Sci. USA, 98, 625-628 (2001).
  24. M. Balass, E. Kalef, S. Fuchs and E. Katchalski-Katzir. A cyclic peptide with high affinity to -bungarotoxin protects mice from the lethal effect of the toxin. Toxicon, 39, 1045-1051 (2001).
  25. S.-H. Im, D. Barchan, P. K. Maiti, S. Fuchs and M. C. Souroujon. Anti-CD40L antibody treatment suppresses chronic experimental myasthenia by down regulation of Th1 differentiation. J. Immunol., 166, 6893-6898 (2001).
  26. T. Scherf, R. Kasher, M. Balass, M. Fridkin, S Fuchs and E. Katchalski-Katzir. A -hairpin structure in a 13-mer peptide that binds -bungarotoxin with high-affinity and neutralizes its toxicity. Proc. Natl. Acad. Sci. USA, 98, 6629-6634 (2001).
  27. S.-H. Im, D. Barchan, P. K. Maiti, L. Raveh, M. C. Souroujon and S. Fuchs. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB Journal, in press, (2001).
  28. M. Harel, R. Kasher, A. Nicolas, J. M. Guss, M. Balass, M. Fridkin, A. B. Smit, K. Brejc, T. Sixma, E. Katchalski-Katzir, J. L. Sussman and S. Fuchs. The structure of the binding site of the acetylcholine receptor as visualized in the X-ray structure of a complex between a-bungarotoxin and a high affinity mimotope peptide. Neuron, in press, (2001).